
Reinilde Heyrman has spent decades turning clinical uncertainty into decisions. Her method is neither grand nor theatrical: start with the science, plan for the detour, and make sure someone owns the next move.
The Cincinnati CRO built a $2.5 billion business by taking on clinical trials that young biotechs cannot run alone - and by keeping the scientists, software, labs and logistics under one roof.